Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095537
Status:
COMPLETED
Last Update Posted:
2010-03-02
First Post:
2004-11-05
Brief Title:
BMS-599626 in Patients With Advanced Solid Malignancies
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase I Study of BMS-599626 in Patients With Advanced Solid Malignancies Including Malignancies That Express HER2 at the Maximum Tolerated Dose andor Recommended Phase II Dose
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to identify the highest oral dose of BMS-599626 a drug that is directed against EGFR and HER2 proteins that can be given safely on a daily schedule of 21 days with a 7 day rest period in patients with cancer who no longer benefit from other commonly used treatments The study will also test for other proteins that may be affected by BMS-599626 and the level of study drug in the blood will be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None